Recipe List

Improvac 100 ml

Descargo de responsabilidad: el producto de la foto puede diferir del producto real.

SKU
90112
Marca:
Zoetis
Batch:
696591
Expiry date:
31-10-2025
Número de registro:
NL: REG NL 101060

Is the registration number of your country not listed? Then this product falls within the cascade control system. For more information, click here (please check the rules of your country, they may deviate).

En stock

Vaccin against Boar Taint for male pigs

Composition

One dose (2 ml) contains: Gonadotropin releasing factor (GnRF) analogue-protein conjugate (a synthetic peptide analogue of GnRF conjugated to diphtheria toxoid) min. 300 mcg

Indications

Induction of antibodies against GnRF to produce a temporary immunological suppression of testicular function. For use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. Another key contributor to boar taint, skatole, may also be reduced as an indirect effect. Aggressive and sexual (mounting) behaviours are also reduced.

The onset of immunity (induction of anti-GnRF antibodies) can be expected within 1 week post second vaccination. Reduction of androstenone and skatole levels has been demonstrated from 4 to 6 weeks post second vaccination. This reflects the time needed for clearance of boar taint compounds already present at the time of vaccination as well as the variability of response between individual animals. Reduction of aggressive and sexual (mounting) behaviours can expected from 1 to 2 weeks

Dosage and administration

Improvac is for subcutaneous use. Entire male pigs from 8 weeks of age onwards should be vaccinated with 2 doses of 2 ml at least 4 weeks apart, with the second dose normally given 4 to 6 weeks prior to slaughter.

One dose (2 ml) contains: Gonadotropin releasing factor (GnRF) analogue-protein conjugate (a synthetic peptide analogue of GnRF conjugated to diphtheria toxoid) min. 300 mcg
© 2024 Grovet B.V. All rights reserved.